Genomics in the Scientific Literature [9] - Ethical, Legal, and Social Issues (ELSI)

Ethical, Legal, and Social Issues (ELSI)
1. Clinical and ethical considerations in pharmacogenetic testing: views of physicians in 3 "early adopting" departments of psychiatry
Hoop JG, et al.
J Clin Psychiatry 2010 Mar

J Clin Psychiatry. 2010 Mar 9. [Epub ahead of print]
Clinical and ethical considerations in pharmacogenetic testing: views of physicians in 3 "early adopting" departments of psychiatry.
Hoop JG, Lapid MI, Paulson RM, Roberts LW.

Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA. jhoop@mcw.edu.
Abstract
OBJECTIVE: Pharmacogenetic testing for polymorphisms affecting drug response and metabolism is now clinically available, and its use in psychiatry is expected to become more widespread. Currently, few clinical and ethical standards exist for the use of these new tests. As a step toward building consensus about testing, we assessed the attitudes and practices of psychiatrists at 3 academic departments of psychiatry where pharmacogenetic testing is clinically available. We hypothesized that testing would be used primarily in treatment-resistant illness and that clinicians would believe such tests carried little risk. METHOD: Residents and faculty at 3 departments of psychiatry considered to be "early adopters" of pharmacogenetic testing were invited during the academic year 2006-2007 to complete an Internet-based survey, including questions regarding clinical practices and opinions about testing utility, risks, and necessary safeguards. RESULTS: The 75 respondents had ordered pharmacogenetic testing a mean of 20.86 times in the previous 12 months. Testing was judged most useful in cases of treatment-resistant depression and medication intolerance. There was a lack of consensus about the risks of testing, particularly the risk of secondary information about disease susceptibility. Respondents endorsed the use of several safeguards, including confidentiality, pretest and posttest counseling, and informed consent, but consensus about other safeguards was lacking. Women and those who had not ordered testing in the prior year were more concerned about risks and need for safeguards than were men and those who had recently ordered testing. CONCLUSIONS: Physicians at early adopting departments of psychiatry endorsed the clinical utility of pharmacogenetic testing and the use of some patient safeguards, but showed a lack of consensus about other safeguards and risks. © Copyright 2010 Physicians Postgraduate Press, Inc.

PMID: 20361898 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20361898?dopt=Abstract



2. Law & psychiatry: Genetic discrimination in mental disorders: the impact of the genetic information nondiscrimination act
Appelbaum PS
Psychiatr Serv 2010 Apr;61(4):338-40

Psychiatr Serv. 2010 Apr;61(4):338-40.
Law & psychiatry: Genetic discrimination in mental disorders: the impact of the genetic information nondiscrimination act.
Appelbaum PS.

Department of Psychiatry, Columbia University. psa21@columbia.edu
Abstract
Genetics is one of the most active areas of research on mental disorders. As genetic tests related to psychiatric disorders and their treatments proliferate in research and clinical settings, the possibility becomes more troubling that such information will be used for purposes other than those for which it was collected. Because of this, the federal Genetic Information Nondiscrimination Act of 2008 is of substantial importance to persons with mental disorders, persons at risk for the conditions, and family members of both groups. This column discusses the process of passing the legislation, along with the implications of the act.

PMID: 20360270 [PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/20360270?dopt=Abstract